|
gptkbp:instanceOf
|
gptkb:drug
immunosuppressive agent
|
|
gptkbp:administeredBy
|
intravenous infusion
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2005
|
|
gptkbp:ATCCode
|
L04AA24
|
|
gptkbp:brand
|
gptkb:Orencia
|
|
gptkbp:CASNumber
|
332348-12-6
|
|
gptkbp:contains
|
gptkb:CTLA-4
IgG1 Fc region
|
|
gptkbp:contraindication
|
serious infections
hypersensitivity to abatacept
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
selective immunosuppressant
|
|
gptkbp:form
|
solution for injection
lyophilized powder for infusion
|
|
gptkbp:halfLife
|
13-16 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abatacept
|
|
gptkbp:interactsWith
|
live vaccines
TNF inhibitors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
selective T-cell co-stimulation modulator
|
|
gptkbp:molecularWeight
|
92 kDa
|
|
gptkbp:monitors
|
liver function tests
infection surveillance
|
|
gptkbp:notRecommendedFor
|
children under 2 years
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
moderate to severe rheumatoid arthritis
polyarticular juvenile idiopathic arthritis
active psoriatic arthritis
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
nausea
headache
hypertension
infections
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:CD80
gptkb:CD86
|
|
gptkbp:UNII
|
3KX376GY7L
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:psoriatic_arthritis
rheumatoid arthritis
|
|
gptkbp:bfsParent
|
gptkb:CD28
|
|
gptkbp:bfsLayer
|
7
|